Sentaur Biosciences
Pioneering Precision Therapeutics for Senescence Driven Diseases
Company Overview
Snapshot
Founded in March 2018 by Valery Krizhanovsky, Sentaur Biosciences operated with 1–10 employees. The company secured funding across three rounds from M Ventures and ExploreBio. In March 2024, Sentaur Biosciences ceased operations.
Business overview
Sentaur Biosciences is a biotech company focused on senescence biology, developing breakthrough treatments for age-related diseases. The company leverages a proprietary library of distinct senescent cell surface proteins, licensed from Prof. Valery Krizhanovsky's lab at the Weizmann Institute of Science. Sentaur Biosciences aims to treat diseases involving senescent cell burden, with an initial focus on oncology and future expansion into debilitating age-related conditions. The company also seeks strategic partnerships to continue discovering and developing surface markers of senescence.
Company Intelligence Q&A
- What is Sentaur Biosciences' primary focus?
- Sentaur Biosciences focuses on senescence biology to discover and develop breakthrough treatments for debilitating age-related diseases, with a primary focus in oncology.
- Who founded Sentaur Biosciences?
- Sentaur Biosciences was founded by Valery Krizhanovsky in March 2018.
- What is the status of Sentaur Biosciences?
- Sentaur Biosciences ceased operations in March 2024.
- What technology underpins Sentaur Biosciences' product development?
- Sentaur Biosciences utilizes a unique MS-based discovery method to identify novel targets on the surface of senescent cells, a technology licensed from the laboratory of Prof. Valery Krizhanovsky.